Tumour-specific HMG-CoAR is an independent predictor of recurrence free survival in epithelial ovarian cancer - PubMed (original) (raw)

Tumour-specific HMG-CoAR is an independent predictor of recurrence free survival in epithelial ovarian cancer

Donal J Brennan et al. BMC Cancer. 2010.

Abstract

Background: Our group previously reported that tumour-specific expression of the rate-limiting enzyme in the mevalonate pathway, 3-hydroxy-3-methylglutharyl-coenzyme A reductase (HMG-CoAR) is associated with more favourable tumour parameters and a good prognosis in breast cancer. In the present study, the prognostic value of HMG-CoAR expression was examined in tumours from a cohort of patients with primary epithelial ovarian cancer.

Methods: HMG-CoAR expression was assessed using immunohistochemistry (IHC) on tissue microarrays (TMA) consisting of 76 ovarian cancer cases, analysed using automated algorithms to develop a quantitative scoring model. Kaplan Meier analysis and Cox proportional hazards modelling were used to estimate the risk of recurrence free survival (RFS).

Results: Seventy-two tumours were suitable for analysis. Cytoplasmic HMG-CoAR expression was present in 65% (n = 46) of tumours. No relationship was seen between HMG-CoAR and age, histological subtype, grade, disease stage, estrogen receptor or Ki-67 status. Patients with tumours expressing HMG-CoAR had a significantly prolonged RFS (p = 0.012). Multivariate Cox regression analysis revealed that HMG-CoAR expression was an independent predictor of improved RFS (RR = 0.49, 95% CI (0.25-0.93); p = 0.03) when adjusted for established prognostic factors such as residual disease, tumour stage and grade.

Conclusion: HMG-CoAR expression is an independent predictor of prolonged RFS in primary ovarian cancer. As HMG-CoAR inhibitors, also known as statins, have demonstrated anti-neoplastic effects in vitro, further studies are required to evaluate HMG-CoAR expression as a surrogate marker of response to statin treatment, especially in conjunction with current chemotherapeutic regimens.

PubMed Disclaimer

Figures

Figure 1

Figure 1

HMG-CoAR Expression in EOC. Examples of immunohistochemical HMG-CoAR staining in EOC with negative, intermediate and strong cytoplasmic expression (5× and 20× magnification) (A). Areas of membranous expression (B) and granular staining (C) were also seen (20× magnification). HMG-CoAR expression was also evident in normal fallopian tube (D) and normal ovarian surface epithelium (E) (20× magnification).

Figure 2

Figure 2

HMG-CoAR is Associated with Prolonged RFS in EOC. Kaplan Meier analysis of manually assessed HMG-CoAR cytoplasmic intensity revealed a trend towards an improved RFS (A) and OS (B). Dichotomization of data as positive versus negative revealed that HMG-CoAR was associated with an improved RFS (C) but not an improved OS (D).

Figure 3

Figure 3

Automated Analysis of HMG-CoAR Protein Expression. Using Genie pattern recognitiion software, tumour and stroma were identified and tumour specific HMG-CoAR was quantified using a colour deconvolution algorithm. The images shown are IHC and mark-up images, markups show different levels of HMG-CoAR as described by the colour coded legend.

Figure 4

Figure 4

HMG-CoAR Autoscore is Associated with an Improved RFS. There was an excellent correlation between automated and manual cytoplasmic intensity (A). A HMG-CoAR autoscore was calculated by combining cytoplasmic intensity and the percentage of positive tumour cells. The distribution of the HMG-CoAR autoscore is illustrated in the histogram (B). Using a threshold of the 25th percentile, an increased HMG-CoAR autoscore was associated with a prolonged RFS (C) but not OS (D).

Similar articles

Cited by

References

    1. Jemal A, Siegel R, Ward E, Hao Y, Xu J, Murray T, Thun MJ. Cancer statistics, 2008. CA Cancer J Clin. 2008;58(2):71–96. doi: 10.3322/CA.2007.0010. - DOI - PubMed
    1. Mo H, Elson CE. Studies of the isoprenoid-mediated inhibition of mevalonate synthesis applied to cancer chemotherapy and chemoprevention. Exp Biol Med. 2004;229(7):567–585. - PubMed
    1. Liao JK. Isoprenoids as mediators of the biological effects of statins. J Clin Invest. 2002;110(3):285–288. - PMC - PubMed
    1. Wejde J, Blegen H, Larsson O. Requirement for mevalonate in the control of proliferation of human breast cancer cells. Anticancer Res. 1992;12(2):317–324. - PubMed
    1. Sivaprasad U, Abbas T, Dutta A. Differential efficacy of 3-hydroxy-3-methylglutaryl CoA reductase inhibitors on the cell cycle of prostate cancer cells. Mol Cancer Ther. 2006;5(9):2310–2316. doi: 10.1158/1535-7163.MCT-06-0175. - DOI - PubMed

Publication types

MeSH terms

Substances

LinkOut - more resources